The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV
Clin Gastroenterol Hepatol. 2020 Oct 15;S1542-3565(20)31431-2.doi: 10.1016/j.cgh.2020.10.018. Online ahead of print.
Jordan E Lake1, Turner Overton2, Susanna Naggie3, Mark Sulkowski4, Rohit Loomba5, David E Kleiner6, Jennifer C Price7, Kara W Chew8, Raymond T Chung9, Kathleen E Corey10
Author information
1Division of Infectious Disease, University of Texas Health Sciences Center at Houston, Houston, Texas. Electronic address: Jordan.E.Lake@uth.tmc.edu.
2Division of Infectious Disease, University of Alabama School of Medicine, Birmingham, AL.
3Division of Infections Disease, Duke University School of Medicine, Durham, NC.
4Division of Infectious Disease, Johns Hopkins School of Medicine, Baltimore, MD.
5Division of Gastroenterology, University of California San Diego School of Medicine, San Diego, CA.
6Center for Cancer Research, National Cancer Institute, Bethesda, MD.
7Division of Gastroenterology, University of California San Francisco School of Medicine, San Francisco, CA.
8Division of Infectious Diseases, University of California Los Angeles School of Medicine, Los Angeles, CA.
9Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
10Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA. Electronic address: kecorey@partners.org.
Abstract
Non-alcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to non-alcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with HIV (PWH), chronic liver disease is the second leading cause of non-HIV-related mortality. Between 20-63% of PWH have NASH, and 14-63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for and treatment of NAFLD in PWH. Here we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis and management of NAFLD in PWH and highlight priorities for research.